110863-06-4

Basic information

• Product Name: Boc-Asp(OBzl)-Val-OBzl
• Synonyms: Boc-Asp(OBzl)-Val-OBzl
• CAS NO: 110863-06-4
• Molecular Weight: 512.603
• Mol File: 110863-06-4.mol

Chemical Properties

• CAS DataBase Reference: Boc-Asp(OBzl)-Val-OBzl(CAS DataBase Reference)
• NIST Chemistry Reference: Boc-Asp(OBzl)-Val-OBzl(110863-06-4)
• EPA Substance Registry System: Boc-Asp(OBzl)-Val-OBzl(110863-06-4)

Safety Data

• Hazardous Substances Data: 110863-06-4(Hazardous Substances Data)

Upstream product

• 21760-98-5 L-valine benzyl ester 
• 118517-08-1 (S)-3-tert-Butoxycarbonylamino-4-isopropoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 16652-76-9 L-valine benzyl ester p-toluenesulfonate salt 
• 17645-49-7 L-valine benzyl ester benzenesulfonate 
• 2462-34-2 L-valine benzyl ester hydrochloride 
• 84890-97-1 (S)-3-tert-Butoxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid benzyl ester 
• 13798-75-9 N^α-t-butoxycarbonylaspartic acid α-N-hydroxysuccinimide ester β-benzyl ester 

Downstream Products

• 194933-86-3 (S)-2-{(S)-3-Benzyloxycarbonyl-2-[2-(tert-butoxycarbonyl-ethyl-amino)-acetylamino]-propionylamino}-3-methyl-butyric acid benzyl ester 
• 194933-87-4 N-ethylglycyl-β-benzyl-aspartyl-valine benzyl ester 
• 194933-88-5 4-[3-({[(S)-2-Benzyloxycarbonyl-1-((S)-1-benzyloxycarbonyl-2-methyl-propylcarbamoyl)-ethylcarbamoyl]-methyl}-ethyl-carbamoyl)-propyl]-piperidine-1-carboxylic acid tert-butyl ester 
• 224577-17-7 N-<<4-<<<(2-methylphenyl)amino>carbonyl>amino>phenyl>acetyl>-L-leucyl-L-(α-O-benzylaspartyl)-L-O-benzylvaline 
• 224577-16-6 N-<<4-<<(phenylamino)carbonyl>amino>phenyl>acetyl>-L-leucyl-L-(α-O-benzylaspartyl)-L-O-benzylvaline 
• 1026795-58-3 Boc-ILDV(OBn)2 
• 1025941-41-6 Boc-YLDV 
• 224577-18-8 N-<(4-hydroxyphenyl)acetyl>-L-leucyl-L-(α-O-benzylaspartyl)-L-O-benzylvaline 
• 224577-20-2 N-(phenylacetyl)-L-leucyl-L-α-(O-benzylaspartyl)-L-O-benzylvaline 
• 224577-03-1 N-tert-butoxycarbonyl-L-leucyl-L-(α-O-benzylaspartyl)-L-valine benzyl ester 

Relevant articles and documents

Thrombus targeting release of the antithrombotic RGDV [...] - RGDV synthesis and application of

The invention relates to a thrombus targeting polyasparagyl-RGDV, and a preparation method and a nanostructure thereof, and also relates to a targeting antithrombotic effect thereof on mouse thrombus models. The clinic application prospect of the polyaspa

The greening of peptide synthesis

The synthesis of peptides by amide bond formation between suitably protected amino acids is a fundamental part of the drug discovery process. However, the required coupling and deprotection reactions are routinely carried out in dichloromethane and DMF, b

NOVEL COMPOUND WITH EFFECTS OF THROMBOLYSIS, FREE RADICAL SCAVENGING AND THROMBUS-TARGETING AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.

RGD-peptides modifying dexamethasone: to enhance the anti-inflammatory efficacy and limit the risk of osteoporosis

Dexamethasone (Dex) is one of the most effective anti-inflammatory glucocorticoids, while the side effect, osteoporosis seriously limits its clinical use. Cell adhesion is involved in the onset of inflammation and osteoporosis, and RGD-peptides are well k

Synthesis, evaluation and 3D QSAR analysis of novel estradiol-RGD octapeptide conjugates with oral anti-osteoporosis activity

To enhance the potency, reduce the side effects and improve oral property of estradiol in estrogen replacement therapy (ERT), 6 novel estradiol-RGD octapeptide conjugates have been prepared. In an ovariectomized mouse osteoporotic model, at an oral dosage

3D QSAR of novel estrogen-RGD peptide conjugates: Getting insight into structural dependence of anti-osteoporosis activity and side effect of estrogen in ERT

To explore the structural dependence of the oral potency and side effect of estrogen-RGD peptide conjugates, here six novel conjugates were prepared via introducing RGD-tetrapeptides into both 3- and 17-positions of estradiol, and introducing RGD-octapept

New ion-exchange cum separation technique: A study for the synthesis of ω-guanidine containing peptides using ω-amino acid as surrogate

This article describes a systematic study for the introduction of ω-guanidine function at a late stage of synthesis using a protected amino group as a surrogate to improve overall yield. This concept was used to design and synthesize pseudo-peptides as GP IIb-IIIa receptor antagonist wherein glycine in endogenous ligand Arg-Gly-Asp (RGD) is replaced by 2-amino-thiazole-4-ylacetic acid (Tha) as a spacer. Further, we describe here a unique salt exchange cum purification technology based on reverse phase (RP-18) medium-pressure liquid chromatography. Copyright Taylor & Francis Group, LLC.

Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol

Selective, tight-binding inhibitors of integrin α4β1 that inhibit allergic airway responses

Integrin α4β1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of α4β1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of cellular fibronectin, are described that employ a novel N-terminal peptide 'cap' strategy. One inhibitor, BIO- 1211, was ~106-fold more potent than the starting peptide and exhibited tight-binding properties (k(off) = 1.4 x 10-4 s-1, K(D) = 70 pM), a remarkable finding for a noncovalent, small-molecule inhibitor of a protein receptor. BIO-1211 was also 200-fold selective for the activated form of α4β1, and it stimulated expression of ligand-induced epitopes on the integrin β1 subunit, a property consistent with occupancy of the receptor's ligand-binding site. Pretreatment of allergic sheep with a 3-mg nebulized dose of BIO-1211 inhibited early and late airway responses following antigen challenge and prevented development of nonspecific airway hyperresponsiveness to carbachol. These results show that highly selective and potent small- molecule antagonists can be identified to integrins with primary specificity for peptide domains other than Arg-Gly-Asp (RGD); they confirm the generality of integrins as small molecule targets; and they validate α4β1 as a therapeutic target for asthma.

Design of a new class of orally active fibrinogen receptor antagonists

The integrin receptor recognition sequence Arg-Gly-Asp was successfully used as a template from which to develop a series of potent, selective, orally active, peptide-based fibrinogen receptor antagonists with a long duration of action. Simple modifications centered on the Arg and Gly residues quickly led to a modified peptide (1) with significantly enhanced ability to inhibit in vitro platelet aggregation. Substitution of the guanidino group in 1 by piperidine provided 3, which showed not only a further increase in potency but also a modest degree of oral efficacy. Finally, exploration of the nature of the C-terminal amino acid, with respect to its side-chain functionality and the carboxy terminus, yielded a group of molecules that showed excellent in vitro potency for inhibiting platelet aggregation, excellent integrin selectivity, a high level of oral efficacy, and an extended duration of action.